First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
25 April 2022 - 11:30PM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM)
(“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical
company, is pleased to announce that the US Patent and Trademark
Office (“US PTO”) has granted the patent regarding the Rapid
Pathogen Infectious Disease Liquid Biopsy Diagnostics (“RPIDD”)
regarding the invention of an unbiased and simultaneous
amplification method for DNA library preparation (US Patent No :
US11,280,028 B1) to A*STAR institution, a Singapore based
institution with whom Aptorum has an exclusive licensing agreement
of the said technology. The RPIDD technology has been exclusively
licensed by Aptorum from A*Star through its subsidiary, Aptorum
Innovations Holding Pte Limited.
The RPIDD invention employs a unique method in preparing DNA
libraries from samples which contain more than one type of nucleic
acids in substantially low amount comparative to non-nucleic acid
molecules in the sample within a remarkably shorter turnaround time
and substantially more simplified steps compared to conventional
methods of preparing DNA library.
Mr. Darren Lui, President and Executive Director of Aptorum
Group Limited comments “Through our collaboration partner A*STAR,
we are extremely delighted that the USPTO has recognised the
uniqueness of our RPIDD technology and hence granted the said
patent. The patented RPIDD method is going to revolutionize the
traditional first line clinical diagnostics for infectious diseases
such as blood culture, PCR (etc), and we are convinced that a rapid
molecular liquid biopsy based diagnostics approach for infectious
diseases will disrupt the current approaches and hence in due
course potentially reduce infected patient’s mortality and
morbidity. We are now spearheading the efforts in the ongoing
clinical validation and pre-commercialisation preparation of our
patented RPIDD.”
About Aptorum’s Rapid Pathogen Identification and Detection
Diagnostics Technology (RPIDD)
RPIDD is an innovative liquid biopsy-driven rapid pathogen
molecular diagnostics technology. Proprietary technologies are
being developed to enrich pathogenic DNA / RNA for analysis through
harnessing the power of Next-Generation Sequencing platforms and
proprietary artificial intelligence-based software analytics with
the goal to rapidly identify and detect any foreign pathogens
(virus, bacteria, fungus, parasites) without bias through its
genome composition and to identify other unknown pathogens and
novel mutated pathogens. RPIDD has been and continues to be
validated in human samples and so far, such testing has been able
to detect pathogens – ranging from bacteria, fungi and viruses in
an unbiased manner. RPIDD is currently under validation
in-human.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a
clinical stage biopharmaceutical company dedicated to the
discovery, development and commercialization of therapeutic assets
to treat diseases with unmet medical needs, particularly in
oncology (including orphan oncology indications) and infectious
diseases. The pipeline of Aptorum is also enriched through (i) the
establishment of drug discovery platforms that enable the discovery
of new therapeutics assets through, e.g. systematic screening of
existing approved drug molecules, and microbiome-based research
platform for treatments of metabolic diseases; and (ii) the
co-development of a novel molecular-based rapid pathogen
identification and detection diagnostics technology with Accelerate
Technologies Pte Ltd, commercialization arm of the Singapore’s
Agency for Science, Technology and Research.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
US Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein.
Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220425005474/en/
Aptorum Group Limited Investor Relations Department
investor.relations@aptorumgroup.com +44 20 80929299 Redchip –
Financial Communications United States Investor relations Dave
Gentry dave@redchip.com +1 407 491 4498 Actifin – Financial
Communications Europe Investor relations Ghislaine Gasparetto
ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Sep 2023 to Sep 2024